Assertio (NASDAQ:ASRT) Stock Rating Upgraded by StockNews.com

Assertio (NASDAQ:ASRT) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Monday.

ASRT has been the topic of a number of other reports. HC Wainwright cut their target price on shares of Assertio from $4.00 to $3.50 and set a “buy” rating on the stock in a report on Wednesday, March 19th. Industrial Alliance Securities set a $1.75 target price on shares of Assertio in a report on Friday, March 14th.

Assertio Trading Up 1.2 %

Shares of Assertio stock opened at $0.63 on Monday. The company has a fifty day simple moving average of $0.73 and a 200-day simple moving average of $0.87. The stock has a market cap of $60.28 million, a price-to-earnings ratio of -0.86, a PEG ratio of 3.25 and a beta of 0.56. Assertio has a 12-month low of $0.51 and a 12-month high of $1.80. The company has a current ratio of 2.01, a quick ratio of 1.57 and a debt-to-equity ratio of 0.30.

Institutional Investors Weigh In On Assertio

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in shares of Assertio in the 3rd quarter worth approximately $203,000. CM Management LLC grew its holdings in Assertio by 23.1% in the fourth quarter. CM Management LLC now owns 400,000 shares of the company’s stock valued at $348,000 after purchasing an additional 75,000 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Assertio in the fourth quarter valued at $64,000. Wealthfront Advisers LLC acquired a new position in shares of Assertio during the 4th quarter worth $53,000. Finally, Sonora Investment Management Group LLC purchased a new stake in shares of Assertio in the 4th quarter worth about $39,000. 48.96% of the stock is currently owned by institutional investors and hedge funds.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.